ACTRN12617001330336已完成1 期
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy Volunteers
Xgene Pharmaceutical Inc.0 个研究点目标入组 50 人开始时间: 2017年9月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
A Phase 1 Single-Center, Randomized, Placebo-Controlled, Double-Blind Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Candidate Topical Antimicrobial (NEO101) in the Reduction of Propionibacterium acnes among Healthy Young Adult MePropionibacterium acnes amongst healthy volunteersSkin - Dermatological conditionsACTRN12606000424505eosil, Inc.30
已完成
1 期
A phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic profiles of OLX10010 in healthy subjects compared to placeboISRCTN64317949OliX Pharmaceuticals, Inc.48
已完成
不适用
A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700anesthesiaNL-OMON41980Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company, Inc.)72
已完成
1 期
A Phase 1 Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GLY-200 in Healthy Adult SubjectsMetabolic and Endocrine - DiabetesType 2 DiabetesACTRN12621000800820Glyscend Pty Ltd64
已完成
不适用
Phase I, Single-Center, Randomized, Placebo-Controlled, Double-Blinded Study with Single Ascending Doses, Evaluating the Safety and Tolerability of T20K, Administered by a 1-hr IV Infusion in Healthy Male VolunteersMultiple SclerosisNL-OMON48273Cyxone AB40